Varenicline: The newest agent for smoking cessation
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
PURPOSE: The pharmacology, pharmacokinetics, clinical efficacy, safety, dosage and administration, and place in therapy of varenicline are reviewed. SUMMARY: Varenicline is the newest therapy approved by the Food and Drug Administration for smoking cessation and the first in its class targeting the neurobiology of nicotine addiction. Varenicline is selective for the alpha4beta2 acetylcholine-receptor subtype as a partial agonist, thus conferring its effect in limiting the reinforcing aspect of the addictive nicotine molecule. Varenicline is completely absorbed orally and not affected by food. Steady state is reached within four days of administration. Three Phase III clinical trials of varenicline have been published. Two studies compared varenicline with bupropion in patients over age 18 years who smoked more than 10 cigarettes daily. When the data of the two trials were pooled, varenicline use was associated with significant improvements in the four-week carbon-monoxide-confirmed continuous quit rate (44.2% at weeks 9-12 compared with bupropion (29.7%) and placebo (17.7%) (p < 0.0001 for each comparison). The third trial found that continuous quit rates were also significantly higher in patients treated with varenicline versus placebo. Varenicline is generally well tolerated. Varenicline has been administered concurrently with warfarin, digoxin, transdermal nicotine, bupropion, cimetidine, and metformin without any clinically significant drug interactions. CONCLUSION: Varenicline, a newly approved agent for smoking cessation, offers a new option to patients who cannot tolerate the adverse effects associated with nicotine-replacement therapy and bupropion. It is also an alternative to consider in patients with contraindications to such therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361 · cited 3×
“3% and 9% for placebo.(12,13) Other common adverse effects observed in over 10% of participants included headache, insomnia, and abnormal dreams.”
BackgroundMethodVarenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930 · cited 2×
“Therefore, varenicline alleviates the symptoms of nicotine craving and withdrawal through its agonist activity while inhibiting the effects of repeated nicotine exposure by its antagonist activity.(5) Figure 1 illustrates varenicline’s mechanism of action at the α4β2 receptor site as a partial agonist.”
BackgroundTonstad, S. (2006) · JAMA · doi:10.1001/jama.296.1.64 · Cited by 660
Cited by
Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice
Aubin, H., Luquiens, A., & Berlin, I. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12116 · Cited by 138
“There are currently no known contraindications to varenicline [79].”
Pharmacotherapy for smoking cessation: present and future
Aubin, H.-J., Karila, L., & Reynaud, M. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796150837 · Cited by 39
Neuropsychiatric Adverse Events of Varenicline: A Systematic Review of Published Reports
Ahmed, A. I. A., Ali, A. N. A., Kramers, C., Härmark, L. V. D., Burger, D. M., & Verhoeven, W. M. A. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31827c0117 · Cited by 34
Are smoking cessation treatments associated with suicidality risk? An overview
Penberthy, J. K., Penberthy, J. M., Harris, M. R., Nanda, S., Ahn, J., Martinez, C. P., Osika, A. O., Slepian, Z. A., Forsyth, J. C., Starr, J. A., et al. (2016) · Substance Abuse: Research and Treatment · doi:10.4137/sart.s33389 · Cited by 6
Metadata
- Authors
- Potts, L. A., & Garwood, C. L.
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-07-01
- Volume
- 64
- Issue
- 13
- Pages
- 1381-1384
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W1969312838
- Cited by
- 40
- References
- 4
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.